With new results, J&J’s $1B gamble on a targeted inflammation drug faces long odds
Izencitinib is a JAK inhibitor, a type of drug that blocks an enzyme involved in inflammation. The drug class is well-established, having already produced multiple ap...
Continue Reading →
